339 RHBDOMYOSARCOMA OF THE CERVIX IN TEENAGERS – IS FERTILITY PRESERVATION A FEASIBLE OPTION?

¹Felicia Elena Buruiana, ²Bindiya Gupta, ¹Kavita Singh. ¹PanBirmingham Gynaecological Cancer Centre, Birmingham City Hospital; Gynaecological Oncology, Birmingham, UK; ²The Pan-Birmingham Gynaecological Oncology Centre, City Hospital; PanBirmingham Gynaecological Cancer Centre, Birmingham City Hospital; Gynaecological Oncology, Birmingham, UK

10.1136/ijgc-2020-ESGO.25

Introduction/Background Embryonal rhabdomyosarcoma (RMS) of the cervix is a rare entity, encountered mainly in the first two decades of life. The literature consists mainly of case reports and few small case series, and no standard treatment guidelines are available. As this is a disease of adolescence, fertility preservation in well selected cases is of paramount importance.

Methodology We report 3 cases of embryonal RMS of the cervix in adolescents, along with their clinical presentation, histopathological features, diagnosis, management tailored to individual cases.

Results To date, two of the patients have been followed for 5 years and the remaining 1 for 2 years.

They all remained asymptomatic, with no evidence of recurrent disease on clinical examination and MRI.

Conclusion The embryonal type of cervical RMS is the most frequent type in this age group. Cervical RMS have good prognosis as usually they present early due to clinical features of bleeding or a mass protruding through the vagina. It should be considered as differential diagnosis for continuous vaginal bleeding in a teenager and should be investigated appropriately. The patients diagnosed with RMS should be managed by multidisciplinary team at cancer centre for best outcomes. Given the young age at diagnosis, fertility sparing treatment maintaining the oncological safety is of paramount importance and is associated with long term survival.

Disclosures Nil to disclose.

346 RISK FACTORS FOR MARGIN POSITIVITY IN LEEP

¹Ozlem Celik, ¹Halise Meltem Batur, ¹Anil Can Yalçın, ¹Nazlı Can Yalçın, ²Utku Akgör, ²Nejat Ozgul, ²M Coskun Salman, ²Murat Gultekin. ¹Hacettepe University Faculty of Medicine; Department of Obstetrics and Gynecology; ²Hacettepe University Faculty of Medicine; Department of Gynecological Oncology

10.1136/ijgc-2020-ESGO.26

Introduction/Background Loop electrosurgical excision procedure (LEEP) is the most frequently used therapeutic approach in pre-invasive cervical diseases. Surgical margin positivity is a big debate among gynecologists and there are several reports showing the importance of HPV 16–18, pap-smear results, age of the patient, or size of the lesion. This study evaluates the risk factors for surgical margin positivity among patients who were subjected to LEEP for pre-invasive cervical lesions in a tertiary colposcopy center.

Methodology Patients with pre-invasive cervical lesions who underwent LEEP were retrospectively evaluated. Patients who were not tested for high-risk HPV were excluded. Patients were evaluated for margin positivity with respect to pap-smear result (normal vs. $\geq$ ASC-US), age (≤ 40 vs. > 40 years), lesion size (≤ 2 cm vs. > 2 cm) and HPV type (16–18 vs. other high-risk HPV). Student-t test and chi-square test were used for comparison.

Abstract 346 Table 1 Comparison of LEEP margine positive vs. negative cases

	Margine positive (+) n(%)	Margine negative (-) n(%)	p
Age (mean)	41,4	40,5	0,4
Age			
≤40	39(49,4)	130(53,7)	0,5
>40	40(50,6)	112(46,3)	0,5
Pap-smear			
Normal	21(26,6)	123(51,0)	<0,001
≥ASC-US	58(73,4)	118(49,0)	<0,001
HPV			
16+/-18	60(75,9)	105(43,4)	<0,001
Others	19(24,1)	137(56,6)	<0,001
Lesion size			
≤2 cm	58(73,4)	180(74,4)	0,8
>2 cm	21(26,6)	62(25,6)	0,8
Lesion size mean (cm)	1,99	1,80	0,06
Total	79	242	

Results A total of 321 patients constituted the study group. Among the study group, 79 (24.6%) patients had margin positivity. Comparison of this group with 242 (75.4%) margin negative patients revealed that abnormal pap-smear and HPV 16 and/or 18 positivity were significantly associated with margin positivity (table 1). Pap-smear abnormality ($\geq$ ASC-US) was seen in 58 (73.4%) of margine positive cases whereas only 118 (49.0%) with margin negativity had abnormal smear ($p < 0.001$, OR: 3.1; 95% CI: 1.7–5.6). This risk association did not differ for different Pap-smear abnormality thresholds (LSIL, HSIL etc). Being positive for HPV 16–18 was also a risk factor for margin positivity (75.9% vs. 43.4%, $p < 0.001$, OR: 4.4; 95%CI: 2.45–7.96). However, neither age ($p = 0.5$) nor the lesion size ($p = 0.8$) was a significant factor for margin positivity. Among 79 margin positive cases, 33 (41.7%) had re-LEEP, 13 (16.5%) had cold-knife conization, 13 (16.5%) had hysterectomy, and 12 (15.1%) were just followed-up while 8 (10.2%) were lost to follow up after the LEEP procedure. Among patients who had re-LEEP or conization ($n = 46$), 7 patients (15.2%) had still positive surgical margine after the second procedure (5 in re-LEEP (15.1%), 2 in cold knife conization (15.4%)).

Conclusion Patients with HPV 16–18 and/or Pap-smear abnormality ($\geq$ ASC-US) should be carefully evaluated before LEEP procedure for a possible margin positivity. In such cases, larger excisions may be considered to decrease the risk of margin positivity especially if the patient has no future fertility desire.

Disclosures No conflict of interest to declare.

359 INDUCTION CHEMOTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER – YAY OR NAY?

¹Pedro Simões, ¹João Godinho, ¹Lúisa Leal-Costa, ¹Mafalda Casa-Nova, ²Fernando Igreja, ²Gustavo Mendinhos, ³Rosa Madureira, ⁴Vanessa Monteiro, ⁵Vera Mendonça, ¹José Passos-Coelho. ¹Hospital Beatriz Ângelo; Medical Oncology; ²Hospital Beatriz Ângelo; Obstetrics and Gynaecology; ³Hospital Beatriz Ângelo; Pathology; ⁴Hospital Beatriz Ângelo; Radiology; ⁵Centro Hospitalar Lisboa Norte, Hospital de Santa Maria; Radiotherapy

10.1136/ijgc-2020-ESGO.27

Introduction/Background Definitive concurrent chemoradiation [dChR] is the standard treatment for locally advanced cervical cancer [LACC]. Although there's insufficient clinical evidence to support it, induction chemotherapy [iChT]